Akcea shows off what Novartis missed and what Pfizer gained, offering more details on PhII cardio data
Back in January Ionis spinoff Akcea teased, in two press releases issued one week apart, topline data suggesting its two up-and-coming antisense oligonucleotides can significantly slashed triglycerides as well as other proteins tied with cardiovascular disease. At the virtual European Society of Cardiology, the biotech finally gets a chance to lay them all out.
As their names suggest, AKCEA-APOCIII-LRx and AKCEA-ANGPTL3-LRx (vupanorsen) target apolipoprotein C-III (APOC-III) and angiopoietin-like 3 (ANGPTL3), respectively. In both Phase II studies being presented at ESC, investigators recruited patients with hypertriglyceridemia and chose fasting triglyceride level as the primary endpoint. Both cleared the bar with a clean safety slate.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 150,300+ biopharma pros reading Endpoints daily — and it's free.